Pharmaceuticals & Life Sciences
Map API-level carbon and meet sustainability obligations at speed.
ICH Q9 and Scope 3 Category 11 are raising the bar on pharmaceutical sustainability. CarbonBright automates LCAs across your product portfolio — from API synthesis to packaged dose.
Why pharma and life sciences companies need product-level carbon data
Investor and CDP Scope 3 scrutiny
Pharmaceutical Scope 3 Category 1 is often 10–20× Scope 1+2 combined. CDP and institutional investors are challenging spend-based estimates with increasing frequency — companies that can't substantiate their numbers face rating downgrades.
CSRD supplier data cascades
Pharma and biotech companies in CSRD scope must disclose Scope 3 — and are cascading PCF data requests to their API and excipient suppliers as a result. Suppliers that respond with verified PCFs are being favored in RFPs and renewals.
Supply chain complexity at scale
Pharmaceutical supply chains span dozens of countries and hundreds of chemical intermediates. Mapping a finished product back to its raw material carbon footprint requires an automated, database-backed approach — manual calculation breaks down at portfolio scale.
The CarbonBright tools pharma teams rely on
Product Carbon Footprint
Calculate a science-backed ISO 14067 PCF for every API, excipient, and finished dosage form. Respond to customer PCF data requests with verified numbers — not spend-based estimates.
Learn more →Scope 3Scope 3
Aggregate product PCFs into a GHG Protocol Scope 3 Category 1 inventory. Export CDP-formatted disclosures with full audit trails — ready for investor and regulator review.
Learn more →LCALife Cycle Assessment
A full product LCA gives you the hotspot analysis to identify which APIs and processes drive the most carbon intensity — and the baseline data for science-based target setting.
Learn more →Ready to replace spend-based Scope 3 estimates?
See how CarbonBright builds science-backed product carbon footprints for pharmaceutical supply chains.
Book a Demo